Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Haemonetics (HAE) Total Liabilities (2016 - 2025)

Historic Total Liabilities for Haemonetics (HAE) over the last 16 years, with Q4 2025 value amounting to $1.6 billion.

  • Haemonetics' Total Liabilities fell 276.85% to $1.6 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $1.6 billion, marking a year-over-year decrease of 276.85%. This contributed to the annual value of $1.6 billion for FY2025, which is 3192.54% up from last year.
  • Per Haemonetics' latest filing, its Total Liabilities stood at $1.6 billion for Q4 2025, which was down 276.85% from $1.6 billion recorded in Q3 2025.
  • Haemonetics' 5-year Total Liabilities high stood at $1.6 billion for Q3 2024, and its period low was $1.1 billion during Q3 2022.
  • Over the past 5 years, Haemonetics' median Total Liabilities value was $1.1 billion (recorded in 2022), while the average stood at $1.3 billion.
  • Data for Haemonetics' Total Liabilities shows a peak YoY increase of 8376.55% (in 2022) and a maximum YoY decrease of 599.8% (in 2022) over the last 5 years.
  • Haemonetics' Total Liabilities (Quarter) stood at $1.1 billion in 2021, then decreased by 0.08% to $1.1 billion in 2022, then grew by 14.07% to $1.3 billion in 2023, then rose by 29.22% to $1.6 billion in 2024, then dropped by 2.77% to $1.6 billion in 2025.
  • Its last three reported values are $1.6 billion in Q4 2025, $1.6 billion for Q3 2025, and $1.6 billion during Q2 2025.